Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - estradiol valerate (in brown tablet); estradiol valerate (in white tablet); norgestrel (in brown tablet) - tablet, sugar coated - 2 mg - estradiol valerate (in brown tablet) 2 mg; estradiol valerate (in white tablet) 2 mg; norgestrel (in brown tablet) 0.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maleic acid; colloidal anhydrous silica; magnesium stearate; maize starch; lactose monohydrate; disodium edetate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: citric acid; pregelatinised maize starch; magnesium stearate; povidone; lactose monohydrate; mannitol; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; mannitol; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; citric acid; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; citric acid; pregelatinised maize starch; mannitol; povidone; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 80 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; povidone; pregelatinised maize starch; mannitol; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; brilliant blue fcf aluminium lake; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; croscarmellose sodium; lactose monohydrate; povidone; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid; lactose monohydrate; magnesium stearate; povidone; croscarmellose sodium; mannitol; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; citric acid; pregelatinised maize starch; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - lurasidone hydrochloride, quantity: 40 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; mannitol; citric acid; croscarmellose sodium; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - lurasidone hydrochloride film-coated tablets are indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).